Abiopharma

🔍 Quaggin Susan E (Executive)

Company: AbbVie Inc. (ABBV)

Report Date: 2025-12-31

Detailed Transactions and Holdings:

• Acquired 68 shares of Stock Equivalent Units at $228.49 per share (Derivative)
  Date: 2025-12-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 707.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2

Footnotes:

• F1: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.
• F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.